STOCK TITAN

IRulya Therapeutics Q3 2026 loss widens to $27.7M

Available on EDGAR Accepted by SEC EDGAR Learn about SEC filing dates
(Moderate)

Sentiment and the balance of points

Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.

Form Type
8-K

Rhea-AI Filing Summary

IRulya Therapeutics Inc. reported a net loss of $27.744 million for the third quarter of 2026, compared with $13.442 million a year earlier. Cash, cash equivalents and investments were $105.241 million as of September 30, 2026, and the company expects that cash position to fund operations through the end of 2028. R&D expense was $5.851 million, versus $8.083 million for the third quarter of 2025; G&A expense was $9.022 million, versus $3.281 million for the same 2025 period. IRulya attributed lower R&D mainly to a $6.9 million decline in eDSP costs following the Quince program wind-down, partly offset by $3.8 million higher LAM-001 costs for PH-ILD Phase 2b start-up. Higher G&A primarily reflected $3.0 million in post-acquisition professional fees and $2.7 million in personnel costs, including one-time severance and retention bonuses.

Phase 2 data from the BOS study after lung transplant are anticipated in the first quarter of 2027; a Phase 2 SAPH study is anticipated to begin in the fourth quarter of 2026. Phase 2 studies in BOS and PH-ILD are ongoing.

1 point · 0 major

How this balance works

Rhea-AI gives every point it takes from this document a weight. Minor counts 1, Moderate 3 and Major 9, so one Major point outweighs several Minor ones. The bar adds up the weights on each side, and when neither side holds more than 65% of the total the balance reads Mixed.

It reads the document as published, with the same rules for every company, and it does not look at what the market expected or at how the stock traded, so a point can be objectively good on a day the stock falls.

Rhea-AI Sentiment measures something else, the tone of the wording.

0 major · 1 point

Hollow bars mark forward-looking points. How the balance works

Positive

  • Moderate point. Forward-looking: it has not happened yet and may not happen.Cash, cash equivalents and investments of $105.241 million are expected to fund operations through the end of 2028.

Negative

  • Moderate pointQuarterly net loss was $27.744 million, compared with $13.442 million a year earlier.

Filing Explained

At September 30, 2026, the filing lists Series C redeemable convertible preferred stock, total liabilities, total assets, and total stockholders’ equity (deficit).

Item 2.02 Results of Operations and Financial Condition Financial
Disclosure of earnings results, typically an earnings press release or preliminary financials.
Item 9.01 Financial Statements and Exhibits Exhibits
Financial statements, pro forma financial information, or exhibit attachments filed with this report.
Cash, cash equivalents and investments $105.241 million As of September 30, 2026; expected to fund operations through the end of 2028.
Research and development expense $5.851 million Three months ended September 30, 2026, compared with $8.083 million for the three months ended September 30, 2025.
General and administrative expense $9.022 million Three months ended September 30, 2026, compared with $3.281 million for the three months ended September 30, 2025.
Net loss $27.744 million Three months ended September 30, 2026, compared with $13.442 million for the three months ended September 30, 2025.
Net loss per share $2.31 per basic and diluted share Three months ended September 30, 2026.
Common shares outstanding 1,017,063 shares As of September 30, 2026.
Anticipated BOS Phase 2 data First quarter of 2027 BOS after lung transplant.
Anticipated SAPH Phase 2 study start Fourth quarter of 2026 Study in SAPH.
bronchiolitis obliterans syndrome (BOS) medical
"data in bronchiolitis obliterans syndrome (BOS) post lung transplant"
Bronchiolitis obliterans syndrome (BOS) is a chronic, often progressive condition in which the smallest airways in the lungs become inflamed and scarred, narrowing like clogged pipes and causing long-term breathing difficulty. Investors monitor BOS because it drives demand for diagnostics, drugs and medical devices, affects outcomes in lung and stem-cell transplant programs, and can influence clinical trial results, regulatory decisions and market opportunities in respiratory and transplant-related healthcare.
pulmonary hypertension associated with interstitial lung disease (PH-ILD) medical
"LAM-001 for the treatment of pulmonary hypertension associated with interstitial lung disease (PH-ILD)"
Pulmonary hypertension associated with interstitial lung disease (PH-ILD) is high blood pressure in the vessels that supply the lungs, arising as a complication of scarring or inflammation of lung tissue. Think of the lungs as a sponge with tiny pipes: when the sponge becomes stiff or scarred, the pipes must work harder and can narrow, which makes breathing and activity harder; for investors, PH-ILD matters because it creates a clear medical need that drives demand for diagnostics, therapies, clinical trials, regulatory decisions, and long-term healthcare costs.
mTOR pathway medical
"targeting the mTOR pathway directly in the lungs"
A cell-signaling network centered on the protein called mTOR that acts like a thermostat for cells, controlling growth, metabolism, protein production and self-cleaning processes (autophagy). It integrates signals about nutrients, energy and stress to decide whether a cell should grow, divide or conserve resources. Investors follow the mTOR pathway because drugs that modify it are pursued for cancers, metabolic and neurodegenerative diseases, influencing clinical trial outcomes, regulatory value and commercial potential.
dry powder inhaled formulation medical
"once-daily dry powder inhaled formulation of rapamycin"
redeemable convertible preferred stock financial
"Series C Redeemable Convertible Preferred Stock"
A redeemable convertible preferred stock is a special class of company shares that combines three features: it pays priority dividends like a safer, higher-ranking share; it can be converted into regular common shares so holders can join in upside; and it can be redeemed, meaning the company can buy it back for cash. For investors this matters because it offers a mix of downside protection and potential upside, but can change ownership stakes (dilution) and cash obligations depending on whether it’s converted or redeemed.
fair value adjustment for contingent consideration financial
"Fair value adjustment for contingent consideration"
Cash, cash equivalents and investments $105.241 million Compared with $17.752 million at December 31, 2025
Research and development expense $5.851 million Compared with $8.083 million for the three months ended September 30, 2025
General and administrative expense $9.022 million Compared with $3.281 million for the three months ended September 30, 2025
Net loss $27.744 million Compared with $13.442 million for the three months ended September 30, 2025
Guidance

The company expects its cash position to fund operations through the end of 2028. Phase 2 BOS data are anticipated in the first quarter of 2027; the Phase 2 SAPH study is anticipated to begin in the fourth quarter of 2026.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What was IRLA’s net loss in the third quarter of 2026?

IRulya reported a net loss of $27.744 million, or $2.31 per basic and diluted share, for the three months ended September 30, 2026. For the three months ended September 30, 2025, net loss was $13.442 million, or $49.83 per basic and diluted share.

How much cash did IRLA have, and how long is its expected runway?

IRulya reported cash, cash equivalents and investments of $105.241 million as of September 30, 2026, and expects that cash position to fund operations through the end of 2028. The September 30 balance sheet also lists total assets of $106.472 million and total liabilities of $28.366 million.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google
Add on Google
NASDAQ false 0001662774 0001662774 2026-11-13 2026-11-13
 
 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

 

 

FORM 8-K

 

 

CURRENT REPORT

Pursuant to Section 13 OR 15(d)

of The Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): November 13, 2026

 

 

IRULYA THERAPEUTICS INC.

(Exact name of registrant as specified in its charter)

 

 

 

Delaware   001-38890   90-1024039

(State or other jurisdiction

of incorporation)

 

(Commission

File Number)

 

(IRS Employer

Identification No.)

 

101 College Street, Suite 210  
New Haven, Connecticut   06510
(Address of principal executive offices)   (Zip Code)

Registrant’s telephone number, including area code: (203) 208-8994

Not applicable

(Former name or former address, if changed since last report)

 

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

 

☐

Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

 

☐

Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

 

☐

Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

 

☐

Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

 

Title of each class

 

Trading
Symbol(s)

 

Name of each exchange
on which registered

Common Stock, par value $0.001 per share   IRLA   The Nasdaq Capital Market

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

 

 
 


Item 2.02.

Results of Operations and Financial Condition.

On November 13, 2026, IRulya Therapeutics Inc. (the “Company”) announced its financial results for the quarter ended September 30, 2026 and provided recent business highlights. A copy of the press release issued in connection with the announcement is furnished as Exhibit 99.1 to this Current Report on Form 8-K.

The information contained in Item 2.02 of this Current Report on Form 8-K (including Exhibit 99.1) shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly provided by specific reference in such filing.

 

Item 9.01.

Financial Statements and Exhibits.

(d) Exhibits

 

Exhibit

Number

   Exhibit Description
99.1    Press Release issued by IRulya Therapeutics Inc., dated November 13, 2026
104    Cover Page Interactive Data File (embedded within the Inline XBRL document)


SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

    IRulya Therapeutics Inc.
    By:  

/s/ John Militello

Date: November 13, 2026     Name:   John Militello
    Title:   Chief Financial Officer

Exhibit 99.1

IRulya Therapeutics Provides Corporate Update and Reports Third Quarter 2026 Financial Results

Name changed from Quince Therapeutics, Inc. to IRulya Therapeutics Inc.; common stock began trading on the Nasdaq Capital Market under the ticker “IRLA” on October 12, 2026

Phase 2 data in bronchiolitis obliterans syndrome (BOS) post lung transplant anticipated in the first quarter of 2027

Cash, cash equivalents and investments of $105.2 million as of September 30, 2026 expected to fund operations through the end of 2028 with multiple Phase 2 clinical data readouts

NEW HAVEN, Conn., November 13, 2026 (GLOBE NEWSWIRE) — IRulya Therapeutics Inc. (Nasdaq: IRLA), a clinical stage biopharmaceutical company focused on the development of novel, disease modifying therapies for serious, underserved diseases, today reported financial results for the third quarter ended September 30, 2026.

“This has been a transformative quarter for our company as we relaunched with a new name and sharpened focus on LAM-001, a potentially first in class inhaled formulation of rapamycin for serious pulmonary diseases,” said Brigette Roberts, M.D., Chief Executive Officer of IRulya Therapeutics. “By targeting the mTOR pathway directly in the lungs, LAM-001 holds promise as a potentially disease modifying intervention designed to simultaneously minimize systemic exposure and side effects in these conditions. With a cash runway sufficient to deliver Phase 2 clinical results from multiple indications, we believe IRulya is in a great position to realize LAM-001’s potential.”

Clinical and Scientific Update

 

  •  

The Company continues to progress LAM-001 development across three clinical indications:

 

  •  

Bronchiolitis Obliterans Syndrome Post Lung Transplant (BOS): The Phase 2 trial of LAM-001 in BOS is fully enrolled, with data anticipated in the first quarter of 2027.

 

  •  

Pulmonary Hypertension Associated with Interstitial Lung Disease (PH-ILD): The Phase 2b trial of LAM-001 in PH-ILD is ongoing, with data anticipated in the first quarter of 2028.

 

  •  

Sarcoidosis Associated Pulmonary Hypertension (SAPH): The Company plans to initiate a Phase 2 study of LAM-001 in SAPH in the fourth quarter of 2026, with data anticipated in the fourth quarter of 2028.


  •  

KOL event: On September 28, 2026, the Company hosted a virtual key opinion leader event on the treatment landscape for PH-ILD and BOS, featuring Aaron B. Waxman, M.D., Ph.D., Paul Yu, M.D., Ph.D., and Steven Hays, M.D. A replay of the event is available here.

Corporate update

 

  •  

Relaunched as IRulya Therapeutics: Effective October 9, 2026, the Company changed its name from Quince Therapeutics, Inc. to IRulya Therapeutics Inc. Common stock began trading on the Nasdaq Capital Market as “IRLA” on October 12, 2026.

 

  •  

Approved Series C Conversion: Stockholders approved the conversion on October 6, 2026, and the Series C preferred stock converted to common stock on October 9, 2026, subject to beneficial ownership limitations set by each holder. Following the Series C preferred conversion, our outstanding common stock is 10,841,470 as of November 5, 2026.

 

  •  

Appointed New Leadership Team: Brigette Roberts, M.D., appointed Chief Executive Officer; John Militello, CPA, appointed Chief Financial Officer; and Keith Fandrick, Ph.D., appointed Chief Operating Officer.

 

  •  

Strengthened Board of Directors: Catherine Bonuccelli, M.D., Leone Patterson, James Valentine, J.D., M.H.S., and Drayton Wise joined the Board.

Third Quarter 2026 Financial Results

Cash position: Cash, cash equivalents and investments were $105.2 million as of September 30, 2026. The Company expects that its cash position will be sufficient to fund operations through the end of 2028.

Research and development (R&D) expense: R&D expense for the three months ended September 30, 2026 was $5.9 million, compared to $8.1 million for the three months ended September 30, 2025. The decrease in R&D expenses is primarily due to the decrease in eDSP program costs of $6.9 million due to the wind down of the Quince program, partly offset by an increase in LAM-001 costs of $3.8 million due to PH-ILD Phase 2b study start-up costs.

General and administrative (G&A) expense: G&A expense for the three months ended September 30, 2026 was $9.0 million, compared to $3.3 million for the three months ended September 30, 2025. The increase in G&A expenses is primarily due to $3.0 million in post-acquisition professional fees and an increase in personnel related costs of $2.7 million primarily due to one-time severance and retention bonuses for terminated employees.


Net loss: IRulya reported a net loss of $27.7 million, or net loss per share of $2.31 per basic and diluted share, for the three months ended September 30, 2026, compared to a net loss of $13.4 million, or net loss per share of $49.83 per basic and diluted share for the three months ended September 30, 2025.

Shares outstanding: 1,017,063 shares of common stock were outstanding as of September 30, 2026.

About LAM-001

LAM-001 is a proprietary, once-daily dry powder inhaled formulation of rapamycin (also known as sirolimus) designed to enhance pulmonary delivery and reduce systemic exposure relative to oral or systemic administration. The mTOR pathway is a central regulator of cell growth, repair, and response to stress. Hyperactivated mTOR is implicated in multiple pulmonary diseases, where inhibition of mTOR with rapamycin has been shown in nonclinical models to reduce or reverse the disease process. IRulya is currently focused on developing LAM-001 in the following indications:

 

  •  

Pulmonary hypertension associated with interstitial lung disease (PH-ILD): a condition which leads to thickening and narrowing of pulmonary blood vessels and progressive cardiopulmonary failure. PH-ILD affects an estimated ~200,000 patients in the US and Europe. Inhibition of mTOR with rapamycin has been shown in nonclinical models of pulmonary hypertension to reverse smooth muscle cell hyperproliferation, to attenuate pulmonary vascular remodeling, and to reduce fibrotic disease activity. A Phase 2a study of LAM-001 achieved clinically meaningful improvements across functional, hemodynamic and biomarker measures in patients with PH-ILD and pulmonary arterial hypertension. A Phase 2b trial (NCT05798923) in PH-ILD is ongoing, and data is anticipated in the first quarter of 2028.

 

  •  

Bronchiolitis obliterans syndrome post lung transplant (BOS): the most common form of chronic transplant rejection in lung transplant patients, with no approved therapy and a median survival of 2.5 years after diagnosis. BOS prevalence is estimated at ~30,000 patients in the US and Europe by 2032. In nonclinical models, rapamycin was shown to reduce epithelial injury, limit fibrocyte migration, and boost anti-inflammatory cell infiltration, attenuating the dysregulated fibrocyte trafficking in BOS that drives airway obstruction. LAM-001 is being evaluated in an ongoing Phase 2 trial in BOS (NCT06018766). The trial is fully enrolled, and data is anticipated in the first quarter of 2027.


  •  

Sarcoidosis-associated pulmonary hypertension (SAPH): a severe complication of pulmonary sarcoidosis with no approved therapy, affecting an estimated ~60,000 patients in the US and Europe. SAPH exhibits the same core mTOR-linked pulmonary vascular remodeling seen in PH-ILD, including smooth muscle hyperproliferation and fibrosis, which drive increased pulmonary pressures and progressive right-heart dysfunction. In addition, hyperactive mTOR in SAPH can promote pulmonary granuloma formation and contribute to vascular distortion, and mTOR inhibition has been demonstrated to reduce granuloma development. The Company plans to initiate a Phase 2 study in SAPH in the fourth quarter of 2026, with data anticipated in the fourth quarter of 2028.

About IRulya Therapeutics Inc.

IRulya Therapeutics Inc. is committed to transforming the lives of patients facing serious, underserved diseases by developing disease-modifying therapies to treat their conditions. The company is currently developing LAM-001 for the treatment of pulmonary hypertension associated with interstitial lung disease (PH-ILD), bronchiolitis obliterans syndrome post lung transplant (BOS), and sarcoidosis associated pulmonary hypertension (SAPH). A Phase 2a clinical study in PH patients has been completed, a Phase 2 clinical study in BOS patients is ongoing, a Phase 2b clinical study in PH-ILD is ongoing, and a Phase 2 clinical study in SAPH is anticipated to begin in the fourth quarter of 2026. By pioneering innovative approaches, the company aims to offer new hope and improved quality of life to patients worldwide.

Forward-Looking Statements

Statements in this news release contain “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995 as contained in Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, which are subject to the “safe harbor” created by those sections. All statements, other than statements of historical facts, may be forward-looking statements. Forward-looking statements contained in this news release may be identified by the use of words such as “believe,” “may,” “should,” “expect,” “anticipate,” “plan,” “estimated,” “potential,” “intend,” “will,” “can,” “seek,” or other similar words. Examples of forward-looking statements include, among others, statements relating to the design and potential benefits of LAM-001, including as a disease-modifying therapy for pulmonary disease; anticipated regulatory and development processes and timelines, including the expected timing to initiate the planned Phase 2 trial of LAM-001 in SAPH; the expected timing for data readouts from the ongoing Phase 2 trial of LAM-001 in BOS and the ongoing Phase 2b trial of LAM-001 in PH-ILD and the planned Phase 2 trial of LAM-001 in SAPH; the estimated patient populations in the U.S. and Europe for PH-ILD, BOS and SAPH; the potential advantages of mTOR inhibitors in PH-ILD, BOS and SAPH; and the Company’s anticipated cash runway, including to fund operations through the end of 2028. Forward-looking


statements are based on IRulya’s current expectations and are subject to inherent uncertainties, risks, and assumptions that are difficult to predict and could cause actual results to differ materially from what the company expects. Further, certain forward-looking statements are based on assumptions as to future events that may not prove to be accurate. Factors that could cause actual results to differ include, but are not limited to: clinical results may not be indicative of results that may be observed in the future, including in larger populations; potential safety and other complications related to LAM-001; the ability to obtain and maintain regulatory approval; competition in the company’s industry; the scope, progress and expansion of developing LAM-001; the size and growth of the market(s) therefor and the rate and degree of market acceptance thereof vis-à-vis alternative therapies; the company’s ability to attract or retain key management, members of the board of directors and other personnel; the company’s ability to fund its operations and clinical development plans, including its anticipated cash runway; the impacts of general macroeconomic and geopolitical conditions on the company’s business and financial position; and other risks and uncertainties described in the section titled “Risk Factors” in the Company’s Quarterly Report on Form 10-Q, filed with the Securities and Exchange Commission (SEC) on August 14, 2026 and other reports as filed with the SEC. Forward-looking statements contained in this news release are made as of this date, and IRulya undertakes no duty to update such information except as required under applicable law.


     Three Months Ended September 30,      Nine Months Ended September 30,  
     2026      2025      2026      2025  

Operating expenses:

           

Research and development

   $ 5,851      $ 8,083      $ 18,158      $ 22,781  

Acquired in-process research and development

     —         —         59,000        —   

General and administrative

     9,022        3,281        29,919        11,412  

Gain on Orphai Acquisition

     —         —         (1,305 )       —   

Gain on sale of subsidiary

     (1,731 )       —         (1,731 )       —   

Intangible asset impairment charge

     —         —         67,808        —   

Fair value adjustment for contingent consideration

     —         2,066        (64,330 )       4,522  
  

 

 

    

 

 

    

 

 

    

 

 

 

Total operating expenses

     13,142        13,430        107,519        38,715  
  

 

 

    

 

 

    

 

 

    

 

 

 

Loss from operations

     (13,142 )       (13,430 )       (107,519 )       (38,715 ) 

Fair value adjustment for debt

     —         (549 )       12,168        (1,494 ) 

Fair value adjustment for warrants

     (14,308 )       291        21,315        (4,173 ) 

Warrant issuance costs

     —         (42 )       (874 )       (914 ) 

lnterest income

     1,024        300        1,768        1,017  

Other (expense) income, net

     (1,620 )       (58 )       255        (174 ) 
  

 

 

    

 

 

    

 

 

    

 

 

 

Net loss before income tax expense

     (28,086 )       (13,488 )       (72,887 )       (44,453 ) 
  

 

 

    

 

 

    

 

 

    

 

 

 

Income tax benefit (expense)

     302        46        5,567        (68 ) 
  

 

 

    

 

 

    

 

 

    

 

 

 

Net loss

   $ (27,744 )     $ (13,442 )     $ (67,320 )     $ (44,521 ) 
  

 

 

    

 

 

    

 

 

    

 

 

 

Net loss per share - basic and diluted (1)

   $ (2.31 )     $ (49.83 )     $ (10.79 )     $ (184.60 ) 
  

 

 

    

 

 

    

 

 

    

 

 

 

Weighted average shares of common stock and in-substance common stock outstanding - basic and diluted (1)

     12,004,791        269,757        6,241,440        241,172  
  

 

 

    

 

 

    

 

 

    

 

 

 

 

     September 30, 2026      December 31, 2025  

Cash, cash equivalents, and investments

   $ 105,241      $ 17,752  

Total assets

     106,472        93,523  

Total liabilities

     28,366        129,237  

Series C Redeemable Convertible Preferred Stock

     143,811        —   

Total stockholders’ equity (deficit)

     (65,705 )       (35,714 ) 

 

(1) 

Adjusted prior period net loss per share and weighted average of common shares outstanding to reflect the 1-for-10 reverse stock split effected on April 10, 2026 and the 1-for-20 reverse stock split effected on June 29, 2026

Contact

Joyce Allaire

LifeSci Advisors, LLC

jallaire@lifesciadvisors.com

Filing Exhibits & Attachments

4 documents

Keep reading